

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



ALIBABA HEALTH INFORMATION TECHNOLOGY LIMITED

阿里健康信息技術有限公司

(Incorporated in Bermuda with limited liability)

(Stock code: 00241)

VOLUNTARY ANNOUNCEMENT

SHARE PURCHASE ON THE MARKET FOR SHARE AWARD SCHEME

This announcement is made by Alibaba Health Information Technology Limited (the “**Company**”, and together with its subsidiaries, the “**Group**”) on a voluntary basis.

The board (the “**Board**”) of directors (the “**Directors**”) of the Company wishes to announce that on May 25, 2022, the Board has resolved to provide funds for the professional trustees of the share award scheme adopted by the Company on November 24, 2014 (the “**Share Award Scheme**”) to purchase shares of the Company (the “**Shares**”) on the market at the prevailing market price (the “**Share Purchase**”) at appropriate times for satisfaction of the vesting of restricted share units (the “**RSUs**”) granted under the Share Award Scheme. The Shares to be purchased pursuant to the Share Purchase shall not exceed the specific mandate to grant share awards under the Share Award Scheme, being 404,676,286 Shares, which is 3% of the Shares in issue as at the date of passing the ordinary resolution approving such specific mandate at the annual general meeting of the Company held on July 30, 2021.

The professional trustees appointed by the Company for the Share Award Scheme (the “**Trustees**”) are Computershare Hong Kong Trustees Limited (for the grant of share awards to non-connected persons) and TMF Trust (HK) Limited (for the grant of share awards to connected persons) (the “**CP Trustee**”). After purchasing the Shares on the market, the Trustees shall hold such Shares on trust and shall transfer such Shares to the grantees following the vesting of the RSUs.

The Board believes that the current price of the Shares traded on-market is undervalued, which represents a good opportunity to purchase Shares for future vesting of the RSUs under the Share Award Scheme. The Board also believes that the Group's current financial resources would enable it to implement the Share Purchase with its internal resources while maintaining solid financial position for the continued growth of the Group's operation. The Share Purchase in the present conditions demonstrates the Board's confidence in the Company's current and long-term business outlook and will also serve to safeguard the interests of the investors and enhance investors' confidence in the Company.

The number of Shares to be purchased under the Share Purchase shall be determined by the Board and/or its authorized persons with reference to market conditions. The Board and/or its authorized persons will monitor the operation of the Share Award Scheme and the status of the Share Purchase having regard to, among other things, the market price of the Shares, the public float position of the Company, the number of Shares purchased by the Trustees and the number of Shares needed to satisfy the RSUs granted or to be granted under the Share Award Scheme and adjust the size of the Share Purchase from time to time.

The Share Purchase will be conducted in accordance with the applicable Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Listing Rules**") and all applicable laws and regulations which the Company is subject to. In particular, in the event that it is determined that there will be insufficient public float as required under the Listing Rules for any proposed purchase of Shares pursuant to the Share Purchase, the Company will adjust the number of Shares to be purchased by the CP Trustee so that the Company will not, as a result of the Share Purchase, fail to meet the minimum public float requirement under Rule 13.32(1) of the Listing Rules.

For and on behalf of the Board
Alibaba Health Information Technology Limited
ZHU Shunyan
Chairman and Chief Executive Officer

Hong Kong, May 25, 2022

As at the date of this announcement, the Board comprises seven Directors, of whom (i) three are executive Directors, namely Mr. ZHU Shunyan, Mr. SHEN Difan and Mr. TU Yanwu; (ii) one is a non-executive Director, namely Mr. LI Faguang; and (iii) three are independent non-executive Directors, namely Mr. LUO Tong, Mr. WONG King On, Samuel and Ms. HUANG Yi Fei (Vanessa).